Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sagittarius Life Science Corp (3205) Fair Value & Analysis

Healthcare · TW · Market cap 3.7B TWD

Price53.50 TWD
Fair Value69.44 TWD
Upside+29.8%
Quality95/100
Evidence: Low Range 52.08 TWD – 86.80 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sagittarius Life Science Corp (3205) currently trades at 53.50 TWD, while our model-based Fair Value estimate is 69.44 TWD — implying the stock looks roughly 29.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Sagittarius Life Science Corp (3205) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 69.44 TWD versus a price of 53.50 TWD — about +30% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 3205?
Our 21-model fair value for Sagittarius Life Science Corp is 69.44 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 53.50 TWD.
What is the quality score of 3205?
Sagittarius Life Science Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.